The stock of Novavax, Inc (NVAX) has gone up by 11.17% for the week, with a -9.74% drop in the past month and a -27.66% drop in the past quarter. The volatility ratio for the week is 9.50%, and the volatility levels for the past 30 days are 10.28% for NVAX. The simple moving average for the last 20 days is 5.38% for NVAX’s stock, with a simple moving average of -32.57% for the last 200 days.
Is It Worth Investing in Novavax, Inc (NASDAQ: NVAX) Right Now?
The 36-month beta value for NVAX is also noteworthy at 3.17. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 1 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for NVAX is 146.57M, and at present, short sellers hold a 27.99% of that float. The average trading volume of NVAX on April 28, 2025 was 4.97M shares.
NVAX) stock’s latest price update
The stock of Novavax, Inc (NASDAQ: NVAX) has decreased by -5.66 when compared to last closing price of 7.07.Despite this, the company has seen a gain of 11.17% in its stock price over the last five trading days. reuters.com reported 2025-04-25 that Federal regulators are asking Novavax to complete an additional clinical trial on its Covid-19 vaccine after previously delaying approval, the Wall Street Journal reported on Friday, citing people familiar with the matter.
Analysts’ Opinion of NVAX
Many brokerage firms have already submitted their reports for NVAX stocks, with BTIG Research repeating the rating for NVAX by listing it as a “Buy.” The predicted price for NVAX in the upcoming period, according to BTIG Research is $19 based on the research report published on February 28, 2025 of the current year 2025.
JP Morgan, on the other hand, stated in their research note that they expect to see NVAX reach a price target of $8. The rating they have provided for NVAX stocks is “Underweight” according to the report published on July 30th, 2024.
NVAX Trading at -7.85% from the 50-Day Moving Average
After a stumble in the market that brought NVAX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -72.05% of loss for the given period.
Volatility was left at 10.28%, however, over the last 30 days, the volatility rate increased by 9.50%, as shares sank -8.13% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -14.81% lower at present.
During the last 5 trading sessions, NVAX rose by +11.17%, which changed the moving average for the period of 200-days by -43.67% in comparison to the 20-day moving average, which settled at $6.33. In addition, Novavax, Inc saw -17.04% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NVAX starting from YOUNG JAMES F, who proposed sale 4,000 shares at the price of $6.10 back on Apr 14 ’25. After this action, YOUNG JAMES F now owns shares of Novavax, Inc, valued at $24,406 using the latest closing price.
King Rachel K., the Director of Novavax, Inc, sale 4,150 shares at $9.02 during a trade that took place back on Dec 13 ’24, which means that King Rachel K. is holding 14,770 shares at $37,435 based on the most recent closing price.
Stock Fundamentals for NVAX
Current profitability levels for the company are sitting at:
- -0.36 for the present operating margin
- 0.73 for the gross margin
The net margin for Novavax, Inc stands at -0.27. The total capital return value is set at -0.6.
Based on Novavax, Inc (NVAX), the company’s capital structure generated -0.59 points at debt to capital in total, while cash flow to debt ratio is standing at -0.38. The debt to equity ratio resting at -0.37. The interest coverage ratio of the stock is -12.1.
Currently, EBITDA for the company is -108.04 million with net debt to EBITDA at 2.77. When we switch over and look at the enterprise to sales, we see a ratio of 1.13. The receivables turnover for the company is 6.3for trailing twelve months and the total asset turnover is 0.44. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.98.
Conclusion
In summary, Novavax, Inc (NVAX) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
